FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2019610102> ?p ?o ?g. }

• W2019610102 endingPage "868" @default.
• W2019610102 startingPage "860" @default.
• W2019610102 abstract "Background. Retrospective studies suggest that dose intensity is an important determinant of outcome in the treatment of patients with a variety of malignant diseases such as breast cancer, ovarian cancer, and lymphoma. Unfortunately, these results have not been clearly substantiated in prospective randomized trials. One problem with these studies may be that the degree of dose escalation is not sufficient to result in an improved outcome because the chemotherapy doses are limited by hematopoietic toxicity. In an attempt to deliver more dose-intensive therapy, the feasibility of the administration of multiple cycles of high dose chemotherapy with hematopoietic progenitor cell and growth factor support was investigated in patients with advanced malignancies. Methods. Nineteen patients with metastatic breast cancer and six patients with refractory non-Hodgkin's lymphoma were initially treated with etoposide (VP-16) (2 gm/m2) and granulocyte-colony stimulating factor (G-CSF). Peripheral blood hematopoietic progenitor cells were collected by leukapheresis and cryopreserved as the patients' leukocyte counts recovered from the nadir induced by VP-16. Patients were then treated with four cycles of mitoxantrone (18 mg/m2), thiotepa (150-200 mg/m2) and cyclophosphamide (4500-5000 mg/m2) as a 48–72 hour continuous infusion followed by infusion of one-quarter of their progenitor cells 48 hours later. All patients also received G-CSF (5 μg/kg/day) until engraftment. Results. A total of 88 of a planned 100 cycles of therapy were administered to these 25 patients. The median time to recovery of an absolute neutrophil count of 500/μl or greater was 13–14 days (range, 7–18 days) and time to recovery of a platelet count of 20,000/μl or greater was 13–14 days (range, 7–16 days) after the initiation of each cycle of chemotherapy. The median number of platelet transfusions required after each cycle was 2–3 (range, 0–18 transfusions) and the number of erythrocyte transfusions was 4 (range, 0–10). The most common toxicity was diarrhea. Prophylactic intravenous antibiotics were administered to avoid fever with neutropenia. Two patients developed interstitial pneumonitis and one patient died. One heavily pretreated patient failed to engraft after the first cycle. Reversible veno-occlusive disease of the liver developed in one patient after the fourth cycle of therapy. Four patients progressed while on therapy. Eight patients were disease free and 13 patients had a partial response or had a positive bone scan as the only evidence of disease at the completion of therapy. Seven patients, two with lymphoma and five with breast cancer (28%), remain progression free with a median follow-up of 24.7 months (range, 17–28 months). Conclusions. Support with hematopoietic progenitor cells and growth factors allows the timely administration of repetitive cycles of high dose chemotherapy, resulting in a significant increase in dose intensity with acceptable toxic." @default.
• W2019610102 created "2016-06-24" @default.
• W2019610102 creator A5005492422 @default.
• W2019610102 creator A5019437477 @default.
• W2019610102 creator A5027454018 @default.
• W2019610102 creator A5027756167 @default.
• W2019610102 creator A5034651124 @default.
• W2019610102 creator A5039361268 @default.
• W2019610102 creator A5069964737 @default.
• W2019610102 date "1995-09-01" @default.
• W2019610102 modified "2023-09-26" @default.
• W2019610102 title "Multiple cycles of high dose chemotherapy supported by hematopoietic progenitor cells as treatment for patients with advanced malignancies" @default.
• W2019610102 cites W1484655458 @default.
• W2019610102 cites W1493996133 @default.
• W2019610102 cites W1573785776 @default.
• W2019610102 cites W1824235478 @default.
• W2019610102 cites W1836115940 @default.
• W2019610102 cites W1857437878 @default.
• W2019610102 cites W1860873974 @default.
• W2019610102 cites W1870673602 @default.
• W2019610102 cites W1889933707 @default.
• W2019610102 cites W1929549982 @default.
• W2019610102 cites W1936035002 @default.
• W2019610102 cites W1958341727 @default.
• W2019610102 cites W2028451463 @default.
• W2019610102 cites W2083616014 @default.
• W2019610102 cites W2229559212 @default.
• W2019610102 cites W2230845873 @default.
• W2019610102 cites W2253920138 @default.
• W2019610102 cites W2257281028 @default.
• W2019610102 cites W2266858607 @default.
• W2019610102 cites W2270235662 @default.
• W2019610102 cites W2318772898 @default.
• W2019610102 cites W2323257964 @default.
• W2019610102 cites W2336768886 @default.
• W2019610102 cites W2341557816 @default.
• W2019610102 cites W4237434210 @default.
• W2019610102 cites W4362046093 @default.
• W2019610102 cites W95806289 @default.
• W2019610102 doi "https://doi.org/10.1002/1097-0142(19950901)76:5<860::aid-cncr2820760521>3.0.co;2-b" @default.
• W2019610102 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/8625190" @default.
• W2019610102 hasPublicationYear "1995" @default.
• W2019610102 type Work @default.
• W2019610102 sameAs 2019610102 @default.
• W2019610102 citedByCount "17" @default.
• W2019610102 countsByYear W20196101022016 @default.
• W2019610102 countsByYear W20196101022017 @default.
• W2019610102 crossrefType "journal-article" @default.
• W2019610102 hasAuthorship W2019610102A5005492422 @default.
• W2019610102 hasAuthorship W2019610102A5019437477 @default.
• W2019610102 hasAuthorship W2019610102A5027454018 @default.
• W2019610102 hasAuthorship W2019610102A5027756167 @default.
• W2019610102 hasAuthorship W2019610102A5034651124 @default.
• W2019610102 hasAuthorship W2019610102A5039361268 @default.
• W2019610102 hasAuthorship W2019610102A5069964737 @default.
• W2019610102 hasBestOaLocation W20196101021 @default.
• W2019610102 hasConcept C10205521 @default.
• W2019610102 hasConcept C121608353 @default.
• W2019610102 hasConcept C126322002 @default.
• W2019610102 hasConcept C141071460 @default.
• W2019610102 hasConcept C143998085 @default.
• W2019610102 hasConcept C201750760 @default.
• W2019610102 hasConcept C2776694085 @default.
• W2019610102 hasConcept C2776755627 @default.
• W2019610102 hasConcept C2777371436 @default.
• W2019610102 hasConcept C2777767877 @default.
• W2019610102 hasConcept C2778119113 @default.
• W2019610102 hasConcept C2778684742 @default.
• W2019610102 hasConcept C2779338263 @default.
• W2019610102 hasConcept C2779968505 @default.
• W2019610102 hasConcept C2780923524 @default.
• W2019610102 hasConcept C28328180 @default.
• W2019610102 hasConcept C530470458 @default.
• W2019610102 hasConcept C54355233 @default.
• W2019610102 hasConcept C71924100 @default.
• W2019610102 hasConcept C86803240 @default.
• W2019610102 hasConcept C90924648 @default.
• W2019610102 hasConceptScore W2019610102C10205521 @default.
• W2019610102 hasConceptScore W2019610102C121608353 @default.
• W2019610102 hasConceptScore W2019610102C126322002 @default.
• W2019610102 hasConceptScore W2019610102C141071460 @default.
• W2019610102 hasConceptScore W2019610102C143998085 @default.
• W2019610102 hasConceptScore W2019610102C201750760 @default.
• W2019610102 hasConceptScore W2019610102C2776694085 @default.
• W2019610102 hasConceptScore W2019610102C2776755627 @default.
• W2019610102 hasConceptScore W2019610102C2777371436 @default.
• W2019610102 hasConceptScore W2019610102C2777767877 @default.
• W2019610102 hasConceptScore W2019610102C2778119113 @default.
• W2019610102 hasConceptScore W2019610102C2778684742 @default.
• W2019610102 hasConceptScore W2019610102C2779338263 @default.
• W2019610102 hasConceptScore W2019610102C2779968505 @default.
• W2019610102 hasConceptScore W2019610102C2780923524 @default.
• W2019610102 hasConceptScore W2019610102C28328180 @default.
• W2019610102 hasConceptScore W2019610102C530470458 @default.
• W2019610102 hasConceptScore W2019610102C54355233 @default.
• W2019610102 hasConceptScore W2019610102C71924100 @default.
• W2019610102 hasConceptScore W2019610102C86803240 @default.
• W2019610102 hasConceptScore W2019610102C90924648 @default.

• next